Dow Jones
39.671,04 -201,95 (-0,51%) Nasdaq
16.801,54 -31,08 (-0,18%) Nikkei 225
38.913,48 +296,38 (+0,77%) EUR/USD
1,0831 +0,0004 (+0,03%) Bitcoin EUR
64.137,62 -445,23 (-0,69%) CMC Crypto 200
1.511,08 -15,33 (-1,00%)
Rani Therapeutics Holdings, Inc. (RANI)
Dopo ore:
| Chiusura precedente | 5,14 |
| Aperto | 5,16 |
| Denaro | 5,14 x 100 |
| Domanda | 5,34 x 100 |
| Min-Max giorno | 5,16 - 5,29 |
| Intervallo di 52 settimane | 1,82 - 8,75 |
| Volume | |
| Media Volume | 152.456 |
| Capitalizzazione | 265,645M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,32 |
| Prossima data utili | 20 mar 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,57 |
GlobeNewswireRani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada. The details of the presentation are as follows: A
- GlobeNewswire
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an oral
- GlobeNewswire
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased payload of up to 20mg enables potential delivery of 90+ additional drug candidates - SAN JOSE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA
